|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
3
|
Li G, Chang H, Zhai YP and Xu W: Targeted
silencing of inhibitor of apoptosis proteins by siRNA: A potential
anti-cancer strategy for hepatocellular carcinoma. Asian Pac J
Cancer Prev. 14:4943–4952. 2013. View Article : Google Scholar
|
|
4
|
Shi YH, Ding WX, Zhou J, He JY, Xu Y,
Gambotto AA, Rabinowich H, Fan J and Yin XM: Expression of X-linked
inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes
metastasis and tumor recurrence. Hepatology. 48:497–507. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang L, Zhao Z, Feng Z, Yin N, Liu G and
Shan B: RNA interference-mediated silencing of Stat5 induces
apoptosis and growth suppression of hepatocellular carcinoma cells.
Neoplasma. 59:302–309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Strieter RM, Burdick MD, Mestas J,
Gomperts B, Keane MP and Belperio JA: Cancer CXC chemokine networks
and tumour angiogenesis. Eur J Cancer. 42:768–78. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han KQ, He XQ, Ma MY, Guo XD, Zhang XM,
Chen J, Han H, Zhang WW, Zhu QG, Nian H, et al: Inflammatory
microenvironment and expression of chemokines in hepatocellular
carcinoma. World J Gastroenterol. 21:4864–4874. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghanem I, Riveiro ME, Paradis V, Faivre S,
de Parga PM and Raymond E: Insights on the CXCL12-CXCR4 axis in
hepatocellular carcinoma carcinogenesis. Am J Transl Res.
6:340–352. 2014.PubMed/NCBI
|
|
9
|
An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu
H, Chen L, Xu J and Lin Z: High CXC chemokine receptor 4 expression
is an adverse prognostic factor in patients with clear-cell renal
cell carcinoma. Br J Cancer. 110:2261–2268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rentoft M, Coates PJ, Loljung L, Wilms T,
Laurell G and Nylander K: Expression of CXCL10 is associated with
response to radiotherapy and overall survival in squamous cell
carcinoma of the tongue. Tumour Biol. 35:4191–4198. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Verbeke H, Struyf S, Laureys G and Van
Damme J: The expression and role of CXC chemokines in colorectal
cancer. Cytokine Growth Factor Rev. 22:345–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyake M, Lawton A, Goodison S, Urquidi V
and Rosser CJ: Chemokine (C-X-C motif) ligand 1 (CXCL1) protein
expression is increased in high-grade prostate cancer. Pathol Res
Pract. 210:74–75. 2014. View Article : Google Scholar
|
|
13
|
Dhawan P and Richmond A: Role of CXCL1 in
tumorigenesis of melanoma. J Leukoc Biol. 72:9–18. 2002.PubMed/NCBI
|
|
14
|
Miyake M, Lawton A, Goodison S, Urquidi V,
Gomes-Giacoia E, Zhang G, Ross S, Kim J and Rosser CJ: Chemokine
(C-X-C) ligand 1 (CXCL1) protein expression is increased in
aggressive bladder cancers. BMC Cancer. 13:3222013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Z, Yang L, Xu J, Zhang X and Wang B:
Enhanced expression and clinical significance of chemokine receptor
CXCR2 in hepatocellular carcinoma. J Surg Res. 166:241–246. 2011.
View Article : Google Scholar
|
|
16
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wani N, Nasser MW, Ahirwar DK, Zhao H,
Miao Z, Shilo K and Ganju RK: C-X-C motif chemokine 12/C-X-C
chemokine receptor type 7 signaling regulates breast cancer growth
and metastasis by modulating the tumor microenvironment. Breast
Cancer Res. 16:R542014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boissière-Michot F, Lazennec G, Frugier H,
Jarlier M, Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le
Pessot F, et al: Characterization of an adaptive immune response in
microsatellite-instable colorectal cancer. OncoImmunology.
3:e292562014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bandapalli OR, Ehrmann F, Ehemann V, Gaida
M, Macher-Goeppinger S, Wente M, Schirmacher P and Brand K:
Down-regulation of CXCL1 inhibits tumor growth in colorectal liver
metastasis. Cytokine. 57:46–53. 2012. View Article : Google Scholar
|
|
21
|
Wang JG, Strong JA, Xie W, Yang RH, Coyle
DE, Wick DM, Dorsey ED and Zhang JM: The chemokine CXCL1/growth
related oncogene increases sodium currents and neuronal
excitability in small diameter sensory neurons. Mol Pain. 4:382008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benelli R, Stigliani S, Minghelli S,
Carlone S and Ferrari N: Impact of CXCL1 overexpression on growth
and invasion of prostate cancer cell. Prostate. 73:941–951. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Killian PH, Kronski E, Michalik KM,
Barbieri O, Astigiano S, Sommerhoff CP, Pfeffer U, Nerlich AG and
Bachmeier BE: Curcumin inhibits prostate cancer metastasis in vivo
by targeting the inflammatory cytokines CXCL1 and -2.
Carcinogenesis. 33:2507–2519. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pecot CV, Rupaimoole R, Yang D, Akbani R,
Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, et al:
Tumour angiogenesis regulation by the miR-200 family. Nat Commun.
4:24272013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jung JJ, Noh S, Jeung HC, Jung M, Kim TS,
Noh SH, Roh JK, Chung HC and Rha SY: Chemokine growth-regulated
oncogene 1 as a putative biomarker for gastric cancer progression.
Cancer Sci. 101:2200–2206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Divella R, Daniele A, Savino E, Palma F,
Bellizzi A, Giotta F, Simone G, Lioce M, Quaranta M, Paradiso A, et
al: Circulating levels of transforming growth factor-beta (TGF-β)
and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of
distant seeding of circulating tumor cells in patients with
metastatic breast cancer. Anticancer Res. 33:1491–1497.
2013.PubMed/NCBI
|
|
28
|
Kavandi L, Collier MA, Nguyen H and Syed
V: Progesterone and calcitriol attenuate inflammatory cytokines
CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell
Biochem. 113:3143–3152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang Y, Zheng T, Song R, Wang J, Yin D,
Wang L, Liu H, Tian L, Fang X, Meng X, et al: Hypoxia-mediated
sorafenib resistance can be overcome by EF24 through Von
Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in
hepatocellular carcinoma. Hepatology. 57:1847–1857. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Novell A, Martinez-Alonso M, Mira M,
Tarragona J, Salud A and Matias-Guiu X: Prognostic value of
c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer.
Virchows Arch. 464:645–654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen SP, Yang Q, Wang CJ, Zhang LJ, Fang
Y, Lei FY, Wu S, Song LB, Guo X and Guo L: Transducin β-like 1
X-linked receptor 1 suppresses cisplatin sensitivity in
nasopharyngeal carcinoma via activation of NF-κB pathway. Mol
Cancer. 13:1952014. View Article : Google Scholar
|
|
33
|
Byrne AJ, Jones CP, Gowers K, Rankin SM
and Lloyd CM: Lung macrophages contribute to house dust mite driven
airway remodeling via HIF-1α. PLoS One. 8:e692462013. View Article : Google Scholar
|
|
34
|
Wang J, Yu F, Jia X, Iwanowycz S, Wang Y,
Huang S, Ai W and Fan D: MicroRNA-155 deficiency enhances the
recruitment and functions of myeloid-derived suppressor cells in
tumor microenvironment and promotes solid tumor growth. Int J
Cancer. 136:E602–E613. 2014. View Article : Google Scholar : PubMed/NCBI
|
